Nordicus Partners files draft information statement
NORD•Nordicus Partners shareholders authorized reincorporation from Delaware to Nevada on November 12, 2026. The company will become Nordicus Biotech, increase authorized common shares to 450 million from 50 million and preferred shares to 50 million from 5 million, and continue trading on Nasdaq under NORD.
1. Reincorporation details
Shareholders authorized Nordicus Partners’ reincorporation from Delaware to Nevada on November 12, 2026, and the company will change its name to Nordicus Biotech. Each outstanding common share will convert into one Nevada corporation common share, and trading will continue on Nasdaq under NORD. The Nevada charter opts out of statutory business-combination restrictions, reducing protections for minority shareholders.




